CNTA: 17 Insider Filings in 3 Days — Reading the Lilly Acquisition's Closing Filing Chain
CNTA logged 17 Form 4 insider filings in 3 days. Forensic read of the proxy-to-delisting filing chain shows why it's a merger close, not a momentum setup.
A cluster of 17 Form 4 insider filings hitting a single ticker in three days will light up any SEC filing screen. The reflex is to call it accumulation before a catalyst. On CNTA (Centessa Pharmaceuticals plc), the filings tell a different story — and the difference between those two readings is the difference between a trade and a trap. This is a forensic walk through the exact filing trail.
TLDR
- CNTA logged 17 Form 4 insider transaction filings on June 24 — the largest insider cluster in the active small-cap universe, ahead of UMH (14), GETY (12), OLMA (11), and SM (10). Float 109,314,729 shares; market cap $6,266,618,015.
- This cluster is not accumulation into a runner — it's the closing mechanics of an acquisition. The High Court of Justice of England and Wales approved the acquisition of Centessa by Lilly (news, June 22).
- June 24 also brought a 25-NSE delisting notification, a POSASR, a batch of post-effective S-8 amendments, and a Schedule 13D — the standard deregistration sequence that accompanies a deal reaching its final stage.
- CNTA carries no dilution chain on file — no active shelf, ATM, warrant, or convertible facilities. A clean capital structure, the opposite of the ~3,000 active shelves and ~2,000 ATM programs across the broader small-cap universe.
- The tradeable lesson: a Form 4 cluster means nothing until you read why. Pair it with the proxy chain — PREM14A (April 17) into DEFM14A (May 7) — and the answer is unambiguous.
What the 17 Form 4 Filings on June 24 Actually Mean
The 17 Form 4 filings on CNTA are insider transactions tied to a merger reaching completion, not insiders building a position ahead of a catalyst. A Form 4 reports a change in an insider's beneficial ownership — a buy, a sell, an option exercise, or a disposition. Seventeen of them landing on the same day, on the same ticker, is a mechanical event: when a company is acquired, every officer and director with equity files a Form 4 to report the disposition or conversion of their shares as the deal terms take effect.
That reading is confirmed by the rest of June 24's filing burst and by the news trail. The acquisition of Centessa by Lilly was approved by the High Court of Justice of England and Wales on June 22 (news). Because Centessa is a UK plc, the deal runs through a scheme of arrangement that requires court sanction — and the court approval on June 22, followed by a 25-NSE delisting notification on June 24, marks the deal moving into its final administrative stage. The 17 Form 4 filings sit inside that same window.
CNTA's 17 filings topped the three-day insider-cluster leaderboard across the active universe:
| Ticker | Form 4 Filings (3 days) | Context |
|---|---|---|
| CNTA | 17 | Acquisition by Lilly — court-approved June 22 |
| UMH | 14 | Insider cluster |
| GETY | 12 | OpenAI licensing deal catalyst (news, June 22) |
| OLMA | 11 | Insider cluster |
| SM | 10 | Insider cluster |
GETY is the instructive contrast: its 12-filing cluster sits alongside a real price move and a real product catalyst — Getty Images' OpenAI content partnership (news, June 22). CNTA's larger cluster sits alongside a delisting notice. Same screen signal, opposite meaning. This is exactly why a raw insider-filing count is a starting point, never a conclusion.
The Filing Timeline: From Merger Proxy to Delisting Notice
The CNTA filing chain reads as a textbook merger sequence, running from the preliminary proxy in April to the delisting notification in June. When you line the filings up by date, the narrative writes itself — no interpretation required, just form types and the order they arrived in.
| Date | Filing | What It Signals |
|---|---|---|
| Apr 17 | PREM14A | Preliminary merger proxy — deal disclosed to shareholders |
| Apr 29 | DEF 14A + ARS | Annual meeting proxy and annual report |
| May 7 | DEFM14A | Definitive merger proxy — terms locked for the shareholder vote |
| Jun 12 | 8-K | Material event disclosure |
| Jun 22 | High Court approval (news) | UK court sanctions the acquisition by Lilly |
| Jun 24 | 25-NSE | Notification of removal from listing — delisting |
| Jun 24 | 17 × Form 4 | Insider transactions tied to the merger |
| Jun 24 | Schedule 13D | Acquirer beneficial-ownership disclosure |
| Jun 24 | POSASR + S-8 POS batch | Deregistration of remaining and employee-plan shares |
Each form type carries a specific meaning, and a forensic reader treats them as a vocabulary:
- PREM14A (April 17) — the preliminary merger proxy. This is the first formal SEC document that tells shareholders a deal exists and lays out the framework. When you see a PREM14A, the company is in play.
- DEFM14A (May 7) — the definitive merger proxy. "DEF" replaces "PRE" once the terms are finalized and the document is cleared for distribution ahead of the shareholder vote. The DEFM14A is where the deal price, structure, and timeline are locked.
- DEFA14A / DFAN14A — additional soliciting materials. Centessa's proxy file carries several of these (the earliest dated March 31), the supplemental communications that surround any contested or scrutinized deal.
- 25-NSE (June 24) — notification of removal from listing. This is the filing that takes the ticker off the exchange. It is the clearest single signal that a deal is crossing the finish line.
- POSASR and S-8 POS (June 24) — post-effective amendments. A POSASR amends an automatic shelf registration; an S-8 POS amends an employee stock-plan registration. In a deal close, the acquirer deregisters securities that will no longer trade publicly.
- Schedule 13D (June 24) — a beneficial-ownership disclosure filed when a party crosses 5% with intent. In an acquisition, this is the acquirer's footprint.
The shareholder-litigation noise that surrounds nearly every merger also showed up in the news trail: investigation notices naming CNTA among other targets appeared on May 11, May 12, May 19, and May 27. These "are shareholders getting a fair deal" inquiries are routine M&A theater — they accompany the proxy, they rarely change terms, and they are not a catalyst.
If you want the deeper primer on reading these documents in sequence, our guide to reading SEC filings for day trading breaks down the form-by-form mechanics, and the INHD forensic filing analysis shows the same approach applied to a dilution-driven squeeze rather than a merger.
Share Structure Impact: A Clean Capital Structure Meets a Cash Buyer
CNTA's share structure carries no active dilution overhang — the dossier surfaces no shelf, ATM, warrant, or convertible facilities on file. With a float of 109,314,729 shares and a market cap of $6,266,618,015, this is a large, liquid name being absorbed by an acquirer, not a micro-cap funding its operations by selling stock into the open market.
That is the single most important structural fact here, and it inverts the usual forensic question. On most tickers we screen, the dilution chain is the story: how many shares can hit the market, at what strike, on what timeline. CNTA has no such chain. The POSASR and S-8 POS filings on June 24 are not new registrations adding supply — they are deregistrations removing securities from public registration as the deal closes. Reading them as fresh dilution would be a category error.
Contrast that with the broader universe, where dilution machinery is everywhere. Across all tracked tickers (approximate counts; exact totals withheld) the active facility base spans:
| Facility Type | Active Facilities (universe-wide) |
|---|---|
| Warrants | ~5,600 |
| Shelves | ~3,000 |
| ATM programs | ~2,000 |
| Convertible notes | ~1,300 |
| Convertible preferred | ~800 |
| S-1 offerings | ~600 |
| Equity lines | ~500 |
And the live pipeline keeps refilling: in the past three days, 21 companies filed 424B5 pricing supplements (from 20 unique tickers), 7 fresh S-3 shelf registrations hit (from 7 tickers), and 362 8-K filings landed across 334 unique tickers. CNTA appears in none of the offering buckets — its three-day activity is concentrated entirely in the merger-close and insider-disclosure forms.
The lesson for share-structure forensics: a Form 4 cluster, a POSASR, and an S-8 POS can all show up on a screen that's tuned for dilution, but they describe the removal of public float in a buyout, not the addition of it. The form type and the surrounding chain tell you which.
Price Action Context: Why There's No Spike to Trade Here
The dossier surfaces no volatile intraday OHLC range for CNTA — there is no session spike to trade, which is exactly what a court-sanctioned acquisition looks like. Once a deal price is fixed in a definitive merger proxy and the court has sanctioned the scheme, the equity converges toward deal terms and the wide, mechanical intraday ranges that define small-cap runners disappear. That absence is itself a data point.
Compare that to what was actually moving on the tape this week. On June 22, the volume-spike board was led by names with real two-way ranges: ENTX printed a +131.7% true MFE (low-to-high across all sessions) on 52.3M shares at 416.1x ADV, driven by positive FDA feedback on its Phase 3 osteoporosis program (press release, June 22-23). EHGO ran a +277.1% MFE on 117.1M shares. GETY offered a +250.0% MFE on 217.7M shares off the OpenAI licensing news. Those are tradeable spikes. CNTA is the opposite profile — a $6.27B name whose price discovery is finished.
The macro backdrop frames why the rest of the board was hot. The call is Small-Cap Leadership: the Russell 2000 (IWM) closed at $298.91, just -0.9% from its 52-week high of $301.50 — at/near its 52-week high — up +3.1% over five days and +2.9% over 20 days. Meanwhile the S&P 500 (SPY) sat at $734.30, -3.4% from its 52-week high, and the Nasdaq 100 (QQQ) at $716.38, -4.3% from its high. When small caps lead the majors like this, momentum setups get more follow-through — which is precisely the environment CNTA is not part of. A merger-arb name doesn't care about IWM's relative strength.
If the float-versus-volume mechanics behind those real movers interest you, float rotation explained covers how supply constraint drives the squeezes that CNTA, with its 109M-share float and fixed deal price, structurally cannot produce.
The Risk and the Opportunity: Merger-Arb Reading vs. Dilution Forensics
The risk on a name like CNTA is not dilution — it's misreading the filing cluster and treating a deal close as a momentum entry. There is no active dilution facility to fear here, so the "buying into an offering" trap that defines so many small-cap blowups does not apply. The actual risk is behavioral: seeing "17 insider filings in 3 days" on a screen and front-running a move that already happened.
The opportunity is methodological, and it generalizes to every ticker you screen. The CNTA chain is a clean training set for separating two filing clusters that look identical on a count-based scanner:
- Merger-close cluster — Form 4 burst arrives alongside a DEFM14A, a 25-NSE, deregistration filings (POSASR, S-8 POS), and an acquirer Schedule 13D. The price is converging, not expanding. Not a momentum setup.
- Pre-catalyst accumulation — insider buys (open-market acquisitions, not dispositions) arrive without a merger proxy or delisting notice, often on a low-float name with a live or imminent SEC offering chain. That is the cluster worth a closer look, because insiders building positions ahead of a catalyst is a genuine market-maker-and-management probe of supply before a move.
Where dilution is the live thread — the ~2,000 active ATM programs, the 21 fresh 424B5 pricing supplements from the past three days — the opportunity cuts both ways. A 424B5 means an offering is live and supply is hitting, which is a risk for anyone holding into it. But the same filings frequently precede a managed run-up: market makers and the company often push a stock higher ahead of pricing a shelf or ATM at better levels, and fast traders can ride that pre-offering move. CNTA simply isn't one of those situations — it has no shelf to price against. Knowing which bucket a ticker sits in is the entire game, and the filing forms tell you.
How to Find These Setups in SNACS
The fastest way to separate a merger close from real accumulation is to read the filing chain, not the filing count — and SNACS surfaces both side by side. Here's the exact workflow.
Start in SEC research. The AI Chat lets you ask, in plain language, what a ticker's filing cluster actually contains — "what merger or offering filings has CNTA made in the last 90 days" — and the Filing Browser lets you read the PREM14A, DEFM14A, and 25-NSE inline with the document viewer. The Dilution Snapshot tells you instantly whether a name has active facilities (shares at risk, lowest exercise price) or, like CNTA, a clean structure with no overhang. That single panel is what tells you a Form 4 cluster is a deal close, not dilution.
Screen in the SNACS scanner. Use the SEC filing type filter to surface tickers with fresh registration or offering filings, and the Dilution Alerts column to flag names with active shelf, ATM, or warrant facilities. Click any ticker to open its ticker details page — you get the chart, the dilution risk panel (active shelf/ATM/warrant/convertible facilities), recent news, and the SEC filing list without leaving the stream. For CNTA, that panel shows no facilities and a news feed full of merger-approval headlines — the read takes seconds.
Save it and let it run. Build a saved scan for "fresh 424B5 or S-3 in the last 3 days" and link it to a Dynamic Watchlist — the scan-to-watchlist auto-sync that repopulates matches in real time, so newly filed offerings appear without you re-running anything. Matched tickers show a colored square in the main stream.
Put genuine accumulation on a playbook. When you do find the real setup — insider buying without a merger proxy, on a low-float name with a live catalyst — build it as a multi-step playbook (historical context, setup, trigger, entry, exit). Live matching monitors every scanner ticker and drops a star indicator the moment a name matches your pattern, with in-app, email, or SMS alerts.
Review your reads in the trading journal. If you traded a filing-driven name, the AI Insights engine analyzes your patterns across setups — including your MFE capture rate and which catalyst types you actually convert on — so you learn whether your filing reads are translating into captured moves. For more on screening live offerings, our primer on reading SEC filings for day trading walks through the scanner-to-research workflow end to end.
What to Watch Next
The CNTA file is effectively closed — once a 25-NSE delisting notice and the deregistration filings are in, the ticker is on its way off the tape, and the merger-arb window with it. The forward-looking value is the template. Watch the active universe for the other kind of insider cluster: Form 4 bursts that arrive without a merger proxy, on names that also carry a live 424B5 or a fresh S-3. Those are where insider activity and a financing chain intersect — the setups worth a deeper look.
With Small-Cap Leadership in force and the Russell 2000 (IWM) pressing its 52-week high, the momentum tape is open. Medical Instruments rotated in hard this week (RVOL 2.06 to 5.93, +188%), and that's the sector to cross-reference against the offering pipeline. Keep the SEC filing screen and the dilution panel open together — the count gets you looking; the chain tells you whether it's worth trading.
FAQ
What does a cluster of Form 4 filings actually signal?
A cluster of Form 4 filings signals concentrated insider activity, but the meaning depends entirely on context. A Form 4 reports a change in an insider's beneficial ownership. When many land at once alongside a merger proxy and a delisting notice — as with CNTA's 17 filings on June 24 — it's the mechanical disposition of insider equity as a deal closes. When the same cluster appears without a merger proxy, on a low-float name with a live catalyst, it can indicate insiders building positions ahead of a move. Read the surrounding filings before drawing a conclusion.
What is a 25-NSE filing and why does it matter?
A 25-NSE is a notification of removal from listing — the filing that takes a security off its exchange. It matters because it's one of the clearest single signals that an acquisition or merger is reaching its final administrative stage. CNTA filed a 25-NSE on June 24, two days after the High Court of Justice of England and Wales approved its acquisition by Lilly.
What is the difference between a PREM14A and a DEFM14A?
A PREM14A is the preliminary merger proxy and a DEFM14A is the definitive version. The "PRE" document is the first formal disclosure that a deal exists and outlines the framework; the "DEF" document is filed once terms are finalized and cleared for distribution ahead of the shareholder vote. CNTA filed its PREM14A on April 17 and its DEFM14A on May 7 — a textbook two-step that confirms a deal in progress.
Does CNTA have any dilution risk from shelf registrations or 424B5 offerings?
No. CNTA carries no dilution chain on file — no active shelf registration, ATM program, warrant, or convertible facility. The POSASR and S-8 POS filings on June 24 are deregistrations that remove securities from public registration as the deal closes, not new offerings adding supply. This is the opposite of a dilution-heavy small-cap.
What is a 424B5 and how is it different from an S-3 shelf registration?
An S-3 is a shelf registration that lets a company register securities for future sale, while a 424B5 is the pricing supplement that prices and activates a specific takedown from that shelf. The S-3 is the loaded gun; the 424B5 means it's firing — an offering is live and supply is hitting the market. In the past three days, 7 companies filed S-3 shelves and 21 filed 424B5 supplements across the universe.
How can I tell a merger-close Form 4 cluster from insider accumulation before a catalyst?
Check what the Form 4 cluster arrives with. A merger close pairs the insider filings with a definitive merger proxy (DEFM14A), a delisting notice (25-NSE), deregistration filings, and an acquirer Schedule 13D — and the price is converging toward deal terms. Pre-catalyst accumulation shows open-market insider buys without a merger proxy, often on a low-float name with a live offering chain and an expanding price range. The SNACS dilution snapshot and filing browser let you confirm which one you're looking at in seconds.
How do I screen for SEC filing catalysts in the SNACS scanner?
In the SNACS scanner, use the SEC filing type filter to surface tickers with fresh registration or offering filings and the Dilution Alerts column to flag active facilities. Click any ticker to open its ticker details page for the dilution risk panel, recent news, and the full filing list. Save the filter as a named scan and link it to a Dynamic Watchlist so newly filed names auto-populate in real time.